CriticalSelective irreversible MAO-B inhibitor×SNRI (serotonin-norepinephrine reuptake inhibitor)
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits the enzyme monoamine oxidase (MAO) type B. At Parkinson's disease doses it acts selectively on MAO-B, but above the recommended 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After selegiline is stopped, enzyme activity returns to normal in about 2 weeks, once the body has made new enzyme (selegiline SmPC, AEMPS). Venlafaxine inhibits the reuptake of serotonin and noradrenaline and has no MAO-inhibiting activity of its own (venlafaxine label, US Food and Drug Administration, FDA). Combined with drugs that slow the breakdown of serotonin, that is, MAO inhibitors, venlafaxine can cause life-threatening serotonin syndrome (venlafaxine SmPC, AEMPS; venlafaxine FDA label). Serotonin syndrome, including fatal cases, has also occurred in people who took selegiline for Parkinson's disease together with antidepressants. The mechanism of these reactions is not fully understood (selegiline FDA label).
Symptoms
Selegiline combined with serotonin and noradrenaline reuptake inhibitors, such as venlafaxine, may cause confusion, hypomania, hallucinations, manic episodes, agitation, myoclonus, overactive reflexes, poor coordination, shivering, tremor, seizures, ataxia, sweating, diarrhoea, fever and high blood pressure. All of these can be part of serotonin syndrome (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Patients who started venlafaxine soon after stopping a monoamine oxidase (MAO) inhibitor, or the other way round, developed tremor, myoclonus, sweating, nausea, vomiting, flushing, dizziness, hyperthermia resembling neuroleptic malignant syndrome and seizures, and some died (venlafaxine SmPC, AEMPS). In its most severe form, serotonin syndrome can resemble neuroleptic malignant syndrome, with high fever, muscle rigidity, rapid swings in pulse and blood pressure and changes in mental state (venlafaxine SmPC, AEMPS).
Management
The combination is contraindicated. The selegiline summary of product characteristics (SmPC) names venlafaxine among the drugs selegiline must not be used with and lists its combination with serotonin and noradrenaline reuptake inhibitors as contraindicated (selegiline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label for transdermal selegiline does the same. The US venlafaxine label contraindicates venlafaxine with any monoamine oxidase (MAO) inhibitor and within 14 days of stopping one (US Food and Drug Administration, FDA). Start venlafaxine no earlier than 14 days after stopping selegiline (selegiline FDA labels; venlafaxine SmPC, AEMPS, for irreversible MAO inhibitors). Selegiline inhibits the enzyme irreversibly, and MAO-B activity takes about 2 weeks to recover (selegiline SmPC, AEMPS). When switching the other way, stop venlafaxine at least 7 days before the first dose of selegiline (venlafaxine SmPC, AEMPS, for irreversible MAO inhibitors; transdermal selegiline FDA label). If the patient is nevertheless taking both drugs and signs of serotonin syndrome appear, stop selegiline and venlafaxine at once and start supportive treatment (transdermal selegiline FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Effexor XR (venlafaxine) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid c848a5d8-ba94-4c84-80e3-0bf35fb8e32e, revised 08/2023, sections 5.4, 7 and 17
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: Emsam (selegiline transdermal system) prescribing information (2020)– FDA label, Viatris Specialty LLC, DailyMed setid b891bd9f-fdb8-4862-89c5-ecdd700398a3, revised 05/2020, section 4
- AEMPS: Ficha técnica: Venlafaxina (nº registro 62402), sección 4.5 (2024)– AEMPS, CIMA, nº registro 62402 (Vandral Retard 150 mg, Viatris), revisión 05/2024, secciones 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Venlafaxina, Vandral Retard 150 mg (nº registro 62402), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62402 (Vandral Retard 150 mg, Viatris), revisión 05/2024, secciones 4.3, 4.4 y 4.5 (inhibidores de la monoaminooxidasa)